BOSTON, MASSACHUSETTS — May 29, 2026 — Bioxytran Inc. (OTCQB: BIXT), a biotechnology company focused on carbohydrate-based therapeutics and oxygen therapeutics, today highlighted the publication of a newly released scientific book that may provide valuable scientific context for future evaluation approaches related to its investigational oxygen therapeutic, BXT-25.
The publication, Physiological Mapping of the Cerebral Cortex in Neuropathology (ISBN: 978-3-032-13018-1), was independently authored by internationally recognized physiologist and researcher Dr. Avraham Mayevsky and published by Springer. The book introduces the concept of Physiological Mapping, a methodology designed to assess tissue metabolism and oxygen utilization in living tissue on a real-time basis.
The research focuses on cerebral physiology and disease models involving ischemic stroke, traumatic brain injury, epilepsy, hypoxia, and other neurological conditions. Through continuous monitoring of metabolic and oxygenation parameters, the work seeks to provide a more detailed understanding of tissue viability during injury and recovery processes.
A key aspect of the publication is the use of an FDA-cleared (510(k)) monitoring technology that Bioxytran holds exclusive rights to utilize. The system measures mitochondrial NADH redox state, an important indicator of cellular oxygen consumption and metabolic activity.
In addition to NADH monitoring, the methodology incorporates simultaneous measurement of:
Together, these measurements create a detailed physiological profile that may help researchers better understand how tissues respond to hypoxia, ischemia, and subsequent recovery.
Bioxytran believes these monitoring approaches may eventually provide useful tools for studying oxygen delivery technologies, including the Company's investigational oxygen therapeutic candidate, BXT-25.
“Understanding oxygen utilization at both the microvascular and mitochondrial level is becoming increasingly important as researchers investigate new approaches to treating hypoxic conditions,” said David Platt, PhD, Chief Executive Officer of Bioxytran. “The physiological mapping methodologies described by Dr. Mayevsky may ultimately provide additional insight into how oxygen diffusion therapies such as BXT-25 interact with tissue metabolism in ischemic environments.”
The publication also examines several physiological mechanisms associated with impaired oxygen delivery and cellular stress.
Topics covered include:
These areas are of particular interest because they involve conditions where oxygen availability and utilization play a significant role in disease progression and tissue recovery.
Bioxytran believes that advances in physiological monitoring may help support future research efforts focused on understanding tissue oxygenation and metabolic function in diseases characterized by hypoxia.
The company believes that emerging technologies capable of generating real-time physiological data may contribute to future evaluation strategies for oxygen therapeutics.
The methodologies described in Dr. Mayevsky's independently authored work provide researchers with additional tools for examining oxygen utilization, mitochondrial function, and tissue viability under conditions of reduced blood flow and oxygen deprivation.
Bioxytran believes improved characterization of hypoxic tissue environments could support:
The publication's emphasis on ischemia, hypoxia, traumatic brain injury, and neurological disorders further highlights the broad scientific interest in diseases associated with impaired oxygen delivery.
The company also believes that real-time metabolic monitoring technologies may provide additional insight into how investigational therapies influence tissue oxygen utilization during research and development activities.
Dr. Mayevsky has collaborated with and advised members of Bioxytran's scientific network for several decades. Bioxytran views relationships with experienced scientific and academic researchers as an important component of its long-term development strategy.
BXT-25 remains an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration for any indication.
BXT-25 is an investigational oxygen therapeutic being developed to transport oxygen throughout the body in a manner similar to red blood cells.
The molecule consists of heme derived from FDA-approved camel blood that is attached to a polysaccharide carrier. Administered intravenously, BXT-25 is designed to facilitate oxygen transport and diffusion into tissues where oxygen availability may be compromised.
The company continues to evaluate the platform's potential in conditions associated with hypoxia, ischemia, and impaired tissue oxygenation.
Bioxytran Inc. is a clinical-stage biotechnology company developing carbohydrate-based therapeutics and oxygen therapeutics for diseases involving viral infection, fibrosis, inflammation, and oxygen deprivation.
Its development pipeline includes galectin antagonists and oxygen transport technologies designed to address significant unmet medical needs across multiple therapeutic areas.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential development, evaluation, applications, and future performance of BXT-25 and physiological monitoring technologies. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Bioxytran undertakes no obligation to update any forward-looking statements except as required by applicable law.
Visit the original announcement:
Bioxytran, Inc.
Website: www.bioxytraninc.com
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
